Nxera Pharma Co. Ltd. (JSS)

Overview

Nxera Pharma Co., Ltd. operates as a biopharmaceutical company, with its sphere of operations spread across notable regions including Japan, Switzerland, the United States, Bermuda, and the United Kingdom. Established in 1990 and headquartered in Tokyo, Japan, Nxera Pharma specializes in developing and marketing a diverse range of biopharmaceutical products. The company has forged strategic collaborations with industry giants such as AbbVie, Biohaven, Genentech Inc., GSK, Pfizer Inc., Neurocrine Biosciences Inc., Novartis International AG, and Verily to enhance its research capabilities and expand its product portfolio.

Products and Services

• Ultibro/Breezhaler & Seebri/Breezhaler: Targeted for the treatment of chronic obstructive pulmonary disease (COPD), these products offer relief and improved breathing for individuals suffering from this condition.
• Enerzair & Breezhaler: Dedicated to asthma patients, these treatments aim to manage and control asthma symptoms, facilitating better respiratory health.
• ORAVI: A novel formulation designed to treat oropharyngeal candidiasis, ORAVI addresses fungal infections in the mouth and throat area, showcasing the company's commitment to tackling a range of infectious diseases.
• PIVLAZ: Developed for the treatment of cerebral vasospasm, PIVLAZ represents Nxera's foray into neurovascular care, aiming to alleviate conditions related to narrowed brain vessels.
• Development Pipeline: Nxera Pharma is actively involved in developing innovative therapies for a variety of health conditions, including:
  • HTL0039732: Aimed at immuno-oncology indications, highlighting the company's contributions to cancer treatment.
  • HTL0048149: Focused on addressing schizophrenia disorders, this product is part of Nxera's commitment to improving mental health treatments.
  • Daridorexant: Developed for treating insomnia, demonstrating Nxera's attention to enhancing sleep quality for those affected.
  • HTL0016878, PF-07081532, PF-07054894, PF-07258669, PF-06954522, NBI-1117569, and NBI-1117570: This range of products targets various conditions including schizophrenia, neuropsychiatric disorders, Type 2 diabetes mellitus and obesity, inflammatory bowel disease, anorexia, metabolic diseases, neurology diseases, and central nervous system (CNS) disorders, illustrating the breadth of Nxera's research and development efforts.
• Preclinical Stage Drugs: Nxera is also pioneering in the development of a GPR35 agonist for inflammatory bowel disease/GI disorders, along with other discovery and preclinical stage drugs, signaling the company's ongoing investment in future therapeutics.